Avlar BioVentures
Overview
Avlar is a biotechnology venture capital company which currently has over Euro150 million under management in Avlar BioVentures Fund I, Avlar BioVentures Fund II and the First Cambridge Gateway Fund. The funds are focused on seed and early-stage investments and are used to invest in biopharmaceutical, small molecule drug discovery, epigenetics, medtech and related biotechnology opportunities, and some technology ventures.
Investment Focus
- Focus on early-stage biotechnology and medical device companies in the United Kingdom
Portfolio Companies
Get the full list of 54,000+ investors
Avlar BioVentures and every other firm and angel in the database — as one spreadsheet you keep.
$19one-time payment · no subscription- All 54,000+ investors — VC firms, private equity, family offices and angels
- The key person to contact at each one, with their job title
- Their work email address
- Their phone number
- Their LinkedIn profile
- Delivered as a single .xlsx file — download it as many times as you like
Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.
Frequently asked questions about Avlar BioVentures
What sectors does Avlar BioVentures invest in?
Avlar BioVentures invests in Medical Devices and Biotechnology, and is based in Madingley, England, United Kingdom. Avlar BioVentures is listed as a vc in the ConnectSafely investor database.
What stage does Avlar BioVentures invest at?
Avlar BioVentures backs companies at Seed and Early Stage.
Which regions does Avlar BioVentures invest in?
Avlar BioVentures invests across United Kingdom.
What companies has Avlar BioVentures invested in?
Avlar BioVentures's portfolio includes CellCentric, Crescendo Biologics, Amura Ltd, Paradigm Therapeutics Ltd and De Novo Pharmaceuticals Ltd.
Last updated · Source: ConnectSafely investor database
